Denmark’s Pharmaceutical Market Value to Decline to $3 Billion by 2020

Denmark’s pharmaceutical market will decline in value from $3.5 billion in 2013 to $3 billion by 2020, with price-cap agreements and high tax rates on pharmaceutical products two of the largest barriers to growth, according to research and consulting firm GlobalData.

The company’s latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Denmark, states that price-cap agreements between the Danish Ministry of Health and the Danish Association of Pharmaceutical Industry have existed since 2008 and continue to limit pharmaceutical market growth as the government aims to keep drug prices down.

This is further exacerbated by the 25% value added tax on pharmaceutical products, which is high compared to other EU countries, restricted sales of over-the-counter medicines and a costly labor force.

However, Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says that there are a number of favorable conditions for the future Danish pharmaceutical market, which will be sustained by increasing demand for medicine and higher healthcare expenditure, as well as government healthcare reforms.

Owide explains: “Denmark’s corporate taxes are to be gradually reduced to 22% by 2016 and the country does not levy capital duty, share transfer duty or wealth taxes. This benign tax environment could encourage pharmaceutical companies to set up business in Denmark.

“Furthermore, the registration of a pharmaceutical product under the national procedure in Denmark takes an average of six to 12 months. This is less than the average time taken by regulatory authorities in the US and EU, which is currently 322 days and 366 days, respectively.”

Owide adds that pharmaceuticals are one of Denmark’s largest export goods. In 2013, the country exported DKK71.3 billion ($12.1 billion) worth of pharmaceutical products, accounting for almost 11.4% of Danish exports.

This report provides information on the healthcare, regulatory, and reimbursement landscape in Denmark. It includes analysis of the pharmaceutical and medical device sectors, comprising market size, segmentation, key drivers and barriers, and annualized market forecasts from 2014 to 2020. It was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com. Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Healthcare sector, or connect with us on: Facebook | LinkedIn | Twitter

​